The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company’s distribution network, Jubilant Life Sciences said in a statement.
“Remdesivir is an effective medicine in the treatment of severe COVID-19 cases. In this critical situation, I am pleased that this medicine was made available by Jubilant in the quick time of two and a half months,” the company quoted the CM as saying.
“It gives us immense pleasure and satisfaction to present ?JUBI-R’, the life-saving medicine, to Chief Minister of Uttar Pradesh Yogi Adityanath,” Jubilant Life Sciences Chairman Shyam S Bhartia said.
The company is donating 1000 vials of JUBI-R through its CSR arm, the Jubilant Bhartia Foundation, he added.
In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc., that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India, the company said.
